212 related articles for article (PubMed ID: 25339042)
1. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.
Zhou WB; Bai M; Jin Y
Int J Tuberc Lung Dis; 2009 Mar; 13(3):381-6. PubMed ID: 19275801
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer.
Cheng D; Kong H; Li Y
Biomarkers; 2013 Aug; 18(5):386-90. PubMed ID: 23688054
[TBL] [Abstract][Full Text] [Related]
5. Endostatin levels in exudative pleural effusions.
Sumi M; Kagohashi K; Satoh H; Ishikawa H; Funayama Y; Sekizawa K
Lung; 2003; 181(6):329-34. PubMed ID: 14749937
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Values of sVEGFR-1 and Endostatin in Malignant Pleural Effusions in Patients with Lung Cancer.
Zhu YY; Wu HM; Liu RY
Clin Lab; 2017 Sep; 63(9):1371-1378. PubMed ID: 28879702
[TBL] [Abstract][Full Text] [Related]
7. Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer.
Chen Y; Liang B; Zhao YJ; Wang SC; Fan YB; Wu GP
Diagn Cytopathol; 2012 Apr; 40(4):287-91. PubMed ID: 22431315
[TBL] [Abstract][Full Text] [Related]
8. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis.
Tian P; Shen Y; Feng M; Zhu J; Song H; Wan C; Chen L; Wen F
Postgrad Med; 2015 Jun; 127(5):529-34. PubMed ID: 25979108
[TBL] [Abstract][Full Text] [Related]
11. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
Matsuyama W; Hashiguchi T; Mizoguchi A; Iwami F; Kawabata M; Arimura K; Osame M
Chest; 2000 Oct; 118(4):948-51. PubMed ID: 11035661
[TBL] [Abstract][Full Text] [Related]
13. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions.
Park DS; Kim D; Hwang KE; Hwang YR; Park C; Seol CH; Cho KH; Kim BR; Park SH; Jeong ET; Kim HR
Yonsei Med J; 2013 Mar; 54(2):396-402. PubMed ID: 23364973
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion.
Zhang Y; Yu LK; Xia N
Asian Pac J Trop Med; 2012 Mar; 5(3):239-42. PubMed ID: 22305792
[TBL] [Abstract][Full Text] [Related]
20. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
